Three-quarters of infants were protected from RSV last season

Important points:

• Three quarters of infants were exposed to maternal RSV vaccine or nilsevimab during the first RSV season.
• Younger mothers and black mothers were less likely to receive maternal vaccines.

Study results show that nearly 80% of infants born in California's health care system were exposed to nilcevimab or maternal RSV vaccines in 2023-2024, the first season in which these vaccines were available. Ta..

Nilsevimab, a monoclonal antibody recommended for maternal vaccines administered between 32 and 36 weeks of gestational age and for infants up to 19 months of age entering their first or second RSV season, isshame of wealth” The United States must protect infants from severe RSV disease.

Karen B. Jacobson, MD, MPH; Researchers at the Vaccine Research Center at Kaiser Permanente in Northern California looked at uptake of these two vaccinations within the health care system from October 17, 2023 to March 31, 2024.

Jacobson et al. reported that of 17,251 infants (51.4% boys; mean maternal age 31.2 years, standard deviation 5.2 years), 77.5% were exposed to nirsevimab or the maternal vaccine. One-third (33.9%) of infants were exposed to maternal vaccine only at a median of 34 days (interquartile range) [IQR]24-46 days before birth). A larger proportion of infants were exposed to nilsevimab alone (40.9%; median age, 4 days; IQR, 2-16 days).

According to the CDC, 17.8% of eligible pregnant women will receive the maternal RSV vaccine between September 22, 2023 and January 31, 2024, and 41.3% of women with infants will receive the maternal RSV vaccine between September 22, 2023 and January 31, 2024. He stated that he had received nirsevimab by March 31st. According to recent data, since December 7, 2024, maternal vaccination coverage has exceeded 35% of pregnant women.

Some infants (2.7%) received both immunizations, and 31.1% of them were born preterm. According to the researchers, 72.7% of the 534 infants born within two weeks of their mothers receiving the maternal-infant vaccine also received nilsevimab, which is consistent with CDC recommendations.

Compared to infants of mothers aged 35 years and older, infants of mothers younger than 25 years were more likely to receive nirsevimab (40.1%, 95% CI, 38.6%-41.5%, vs. 44.2%, 95% CI , 41.9%) -46.5%) but less likely to be exposed to maternal vaccines (37.9%; 95% CI, 36.5%-39.4% vs. 26.4%, 95% CI, 24.3%-28.4%).

Infants of Asian women were most likely to be exposed to maternal vaccine or nilsevimab (86.7%, 95% CI, 85.7%-87.7%), whereas infants of Black women had the lowest vaccination coverage (70.2%). %, 95% CI, 67.3%). -72.9%), according to the authors. These numbers reflect data from the CDC, which found that non-Hispanic Asian women had the highest maternal vaccination rates and non-Hispanic black women had the lowest uptake (24.8% and 10.3%, respectively). It has been reported.

Infants of black and Asian mothers had similar rates of nilsevimab uptake, 42.3% (95% CI, 39.2%-45.4%) and 42.7% (95% CI, 41.2%-44.1%), respectively; The proportion was lower among infants of mothers of white mothers (36.6%; 95% CI, 35.3%-37.9%);

“Infants of young mothers and black mothers (a historically undervaccinated group) have lower overall RSV protection, which appears to be driven more by disparities in maternal RSVpreF vaccination than infant nirsevimab.” ,” write Jacobson et al. “A sufficient supply of two different RSV prophylaxis methods may have contributed to the increased proportion of infants being protected from RSV, which may help reduce disparities.”

References:

Publisher:

Information source/disclosure information

collapse

Disclosure: Jacobson reports receiving grants from Pfizer. Please refer to this study for relevant financial disclosures of all other authors.

Add topics to email alerts

Receive an email when a new article is posted

Enter your email address to receive emails when new articles are posted. .

” data-action=”subscribe”> Subscribe

Your request could not be processed. Please try again later. If this issue continues to occur, please contact us [email protected].

Return to Helio